IDEXX Laboratories Stock Forecast
NASDAQ: IDXXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDXX analyst consensus
Consensus (13 analysts)
buy
Avg. price target
$701.33+35.39%
- Strong buy 4
- Buy 4
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering IDEXX Laboratories (2026-10-07), 8 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $701.33, with a high estimate of $805.00 and a low estimate of $470.00. The average target implies upside of 35.4% from the current price of $518.00.
The spread between the highest and lowest targets is 71.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IDXX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 31% |
| Buy | 4 | 31% |
| Hold | 4 | 31% |
| Sell | 0 | 0% |
| Strong sell | 1 | 8% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $470.00 | -9.27% |
| Average target | $701.33 | +35.39% |
| High target | $805.00 | +55.41% |